Solanezumab (anti-Aβ monoclonal) failed primary cognitive endpoints in EXPEDITION1 and EXPEDITION2 Phase III trials in mild-moderate Alzheimer's. Class-leading early test of the anti-Aβ MAb hypothesis in symptomatic AD; outcome reduces confidence in amyloid-cascade-as-drug-target in mild-moderate AD.

Evidence span

Solanezumab (anti-Aβ monoclonal) failed primary cognitive endpoints in EXPEDITION1 and EXPEDITION2 Phase III trials in mild-moderate Alzheimer's. Class-leading early test of the anti-Aβ MAb hypothesis in symptomatic AD; outcome reduces confidence in amyloid-cascade-as-drug-target in mild-moderate AD.

From Rachelle S. Doody et al. 2014, New England Journal of Medicine

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Human, mild-moderate AD; EXPEDITION1 (n=1012) + EXPEDITION2 (n=1040). Solanezumab IV vs placebo. ADAS-Cog11/14 + ADCS-ADL primary endpoints. NCT00904683/NCT00905372.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required